Ultragenyx Pharmaceutical Inc. buy JPMorgan Chase & Co.
Start price
27.02.24
/
50%
€49.60
Target price
27.02.25
€81.12
Performance (%)
-1.21%
Price
03.10.24
€49.00
Summary
This prediction is currently active. With a performance of -1.21%, the BUY prediction for Ultragenyx Pharmaceutical Inc. by JPMorgan_Chase___Co_ is down slightly. This prediction currently runs until 27.02.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Ultragenyx Pharmaceutical Inc. | 1.240% | 1.240% |
iShares Core DAX® | -1.114% | 3.430% |
iShares Nasdaq 100 | 1.816% | 6.911% |
iShares Nikkei 225® | 2.113% | 5.501% |
iShares S&P 500 | 2.038% | 5.327% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $84.00 to $88.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat